ofloxacin has been researched along with Escherichia coli Infections in 88 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Escherichia coli Infections: Infections with bacteria of the species ESCHERICHIA COLI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis." | 9.16 | Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. ( Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC, 2012) |
| "Single-dose treatment with azithromycin (1000 mg) and loperamide is as effective as single-dose treatment with levofloxacin (500 mg) and loperamide for noninflammatory diarrhea." | 9.12 | Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. ( Frenck, RW; Johnston, JR; Monteville, MR; Putnam, SD; Riddle, MS; Rockabrand, DM; Sanders, JW; Tribble, DR; Ulukan, S, 2007) |
| "To investigate the safety, efficacy and recurrence-inhibiting effect of a single dose of levofloxacin (LVFX) for the treatment of acute uncomplicated cystitis in women, 56 females with acute uncomplicated cystitis between 17 and 73 years old were studied, based on the urinary tract infection (UTI) drug efficacy evaluation." | 9.09 | [Efficacy of single-dose therapy with levofloxacin for acute cystitis: comparison to three-day therapy]. ( Amazutsumi, K; Harada, T; Kawamura, H; Koyama, Y; Matsuda, T; Mikami, O; Murota, T; Ohara, T; Uchida, J, 2000) |
| "A single dose of 100 mg ofloxacin was compared with a multiple dose of cotrimoxazole in lower urinary tract infections in 137 women." | 9.06 | Failure of a single dose of 100 mg ofloxacin in lower urinary tract infections in females. ( Forsgren, A; Ode, B; Walder, M, 1987) |
| "The combination of levofloxacin and α1 adrenergic antagonist treatment is the current preferred choice for both bacterial and non-bacterial prostatitis." | 7.79 | Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis. ( He, HX; He, Y; Qin, GD; Xiao, MZ; Yang, J; Zeng, Y; Zhou, YD, 2013) |
| "The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices." | 7.77 | [Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011) |
| "We evaluated, by Monte Carlo simulation, 500-mg once-daily, 100-mg thrice-daily, 200-mg twice-daily, and 200-mg thrice-daily dose regimens of levofloxacin (LVFX), for the ratio of area under the concentration-time curve for 24 h (AUC(0-24)) to minimum inhibitory concentration (MIC) (AUC(0-24)/MIC) and the ratio of maximum plasma concentration (C(max)) to MIC (C(max)/MIC), which predict microbiological outcomes, and the C(max)/MIC, which inhibits fluoroquinolone resistance selection, in complicated urinary tract infections (UTIs) with Escherichia coli or Pseudomonas aeruginosa." | 7.77 | Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa. ( Deguchi, T; Matsumoto, T; Seike, K; Yasuda, M, 2011) |
| "The objective of this study was to assess the in vitro activity of levofloxacin compared to other antibiotics against Escherichia coli strains isolated from female patients with acute pyelonephritis in 23 French hospitals in 2005." | 7.74 | [In vitro activity of levofloxacin against Escherichia coli strains in acute pyelonephritis, in France in 2005]. ( Dib-Smahi, C; Lascols, C; Soussy, CJ, 2007) |
| "Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E." | 7.74 | In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. ( Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2007) |
| "This pilot study was undertaken to characterise the pharmacokinetics, pharmacodynamics and potential clinical efficacy of levofloxacin 750 mg once daily for 5 days for treatment of women with acute uncomplicated pyelonephritis." | 7.74 | Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ( Bryski, L; Duckworth, H; Harding, G; Nicolle, L; Sitar, D; Zhanel, G, 2008) |
| "The aim of this study was to evaluate the in vitro activity of levofloxacin (LVX) in comparison to nalidixic acid (NAL), ofloxacin (OFX), norfloxacin (NOR), amoxicillin (AMX), cefixime (CFM), cotrimoxazole (SXT) and nitrofurantoin (FT), against 402 strains recently isolated from urine specimens in outpatient women suffering from lower urinary tract infections for which short-term treatment was not indicated." | 7.73 | [Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community]. ( Dib, C; Durand, C; Moniot-Ville, N; Weber, P, 2005) |
| "The in vivo efficacy of ofloxacin was compared with those of cefotaxime and doxycycline in a rat model of epididymitis due to Escherichia coli." | 7.68 | Comparative efficacies of ofloxacin, cefotaxime, and doxycycline for treatment of experimental epididymitis due to Escherichia coli in rats. ( Jantos, C; Schiefer, HG; Schmidts, HL; Vieler, E; Weidner, W, 1993) |
| "A mouse model of subcutaneous abscess was used to determine the penetration into the abscess and the preventive value of ofloxacin (Hoe 280)." | 7.67 | Efficacy of ofloxacin (HOE 280) in a model of subcutaneous abscess: penetration and prevention of abscess formation. ( García Iglesias, MC; Perea, EJ, 1986) |
| " Among 33 patients given ofloxacin, the concentration of the drug in vaginal fluid during one dosage interval ranged from 1." | 6.66 | Pharmacodynamic evaluation of ofloxacin and trimethoprim-sulfamethoxazole in vaginal fluid of women treated for acute cystitis. ( Brust, P; Hooton, TM; Johnson, CR; Opheim, K; Stamm, WE; Tartaglione, TA, 1988) |
| "Fluoroquinolones are the most commonly used prophylactic antimicrobials for ultrasound-guided transrectal prostate biopsy due to their broad pathogen spectrum, pharmacokinetics, bioavailability and ease of oral administration." | 6.44 | Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. ( Fujisawa, M; Miura, T; Nakano, Y; Shigemura, K; Takenaka, A; Tanaka, K, 2008) |
| "Levofloxacin is a synthetic fluoroquinolone that is usually used to treat chronic bacterial prostatitis." | 5.16 | Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients. ( Guo, YL; Jin, FS; Liu, DM; Shen, ZJ; Sun, YH; Zhang, ZC, 2012) |
| "Single-dose treatment with azithromycin (1000 mg) and loperamide is as effective as single-dose treatment with levofloxacin (500 mg) and loperamide for noninflammatory diarrhea." | 5.12 | Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. ( Frenck, RW; Johnston, JR; Monteville, MR; Putnam, SD; Riddle, MS; Rockabrand, DM; Sanders, JW; Tribble, DR; Ulukan, S, 2007) |
| "The objective of this multicenter, randomized, controlled, parallel group trial was to evaluate the efficacy of levofloxacin 250 mg oral, once daily (LVFX), placebo one tablet oral once daily (Placebo [P] group) and ciprofloxacin (CPFX) 500 mg oral, twice daily (single blind), prophylaxis in preventing bacteriuria (> or = 10(3) CFU/ml) in post-surgical catheterized patients." | 5.12 | A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones. ( Drago, L; Esposito, S; Leone, S; Marchetti, F; Marvaso, A; Noviello, S, 2006) |
| "To investigate the safety, efficacy and recurrence-inhibiting effect of a single dose of levofloxacin (LVFX) for the treatment of acute uncomplicated cystitis in women, 56 females with acute uncomplicated cystitis between 17 and 73 years old were studied, based on the urinary tract infection (UTI) drug efficacy evaluation." | 5.09 | [Efficacy of single-dose therapy with levofloxacin for acute cystitis: comparison to three-day therapy]. ( Amazutsumi, K; Harada, T; Kawamura, H; Koyama, Y; Matsuda, T; Mikami, O; Murota, T; Ohara, T; Uchida, J, 2000) |
| "A single dose of 100 mg ofloxacin was compared with a multiple dose of cotrimoxazole in lower urinary tract infections in 137 women." | 5.06 | Failure of a single dose of 100 mg ofloxacin in lower urinary tract infections in females. ( Forsgren, A; Ode, B; Walder, M, 1987) |
| "The combination of levofloxacin and α1 adrenergic antagonist treatment is the current preferred choice for both bacterial and non-bacterial prostatitis." | 3.79 | Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis. ( He, HX; He, Y; Qin, GD; Xiao, MZ; Yang, J; Zeng, Y; Zhou, YD, 2013) |
| "We evaluated, by Monte Carlo simulation, 500-mg once-daily, 100-mg thrice-daily, 200-mg twice-daily, and 200-mg thrice-daily dose regimens of levofloxacin (LVFX), for the ratio of area under the concentration-time curve for 24 h (AUC(0-24)) to minimum inhibitory concentration (MIC) (AUC(0-24)/MIC) and the ratio of maximum plasma concentration (C(max)) to MIC (C(max)/MIC), which predict microbiological outcomes, and the C(max)/MIC, which inhibits fluoroquinolone resistance selection, in complicated urinary tract infections (UTIs) with Escherichia coli or Pseudomonas aeruginosa." | 3.77 | Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa. ( Deguchi, T; Matsumoto, T; Seike, K; Yasuda, M, 2011) |
| "The aim of this prospective observational study was to present relevant data on the efficacy and safety of levofloxacin in the treatment of chronic bacterial prostatitis (NIH-II) in the daily clinical routine of urologists in their practices." | 3.77 | [Practice management of chronic bacterial prostatitis with levofloxacin]. ( Naber, KG; Roscher, K; Wagenlehner, F, 2011) |
| "Minimum inhibitory concentrations (MICs) and mutant prevention concentrations (MPCs) of prulifloxacin against 30 strains of Escherichia coli isolated from urinary tract infections as well as the 'biological cost' related to acquisition of resistance to the same drug in 10 uropathogenic E." | 3.74 | In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance. ( Gualco, L; Marchese, A; Schito, AM; Schito, GC, 2007) |
| "The objective of this study was to assess the in vitro activity of levofloxacin compared to other antibiotics against Escherichia coli strains isolated from female patients with acute pyelonephritis in 23 French hospitals in 2005." | 3.74 | [In vitro activity of levofloxacin against Escherichia coli strains in acute pyelonephritis, in France in 2005]. ( Dib-Smahi, C; Lascols, C; Soussy, CJ, 2007) |
| "Because of high rates of trimethoprim-sulfamethoxazole resistance in Escherichia coli, Denver Health switched to levofloxacin as the initial therapy for urinary tract infections (UTIs) in 1999." | 3.74 | Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. ( Burman, WJ; Everhart, RM; Johnson, L; MacKenzie, TD; Mehler, PS; Price, CS; Rome, M; Rozwadowski, J; Sabel, A, 2008) |
| "This pilot study was undertaken to characterise the pharmacokinetics, pharmacodynamics and potential clinical efficacy of levofloxacin 750 mg once daily for 5 days for treatment of women with acute uncomplicated pyelonephritis." | 3.74 | Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis. ( Bryski, L; Duckworth, H; Harding, G; Nicolle, L; Sitar, D; Zhanel, G, 2008) |
| "After antibiotic prophylaxis with metronidazole and levofloxacin, a transrectal sextant biopsy was performed under the guide of transrectal ultrasonography (TRUS) for a 75-year-old suspicious patient with prostate adenocarcinoma." | 3.73 | Life-threatening meningitis resulting from transrectal prostate biopsy. ( Chen, SW; Shen, ZJ; Wang, H; Zhao, JP; Zhou, XL, 2005) |
| "The aim of this study was to evaluate the in vitro activity of levofloxacin (LVX) in comparison to nalidixic acid (NAL), ofloxacin (OFX), norfloxacin (NOR), amoxicillin (AMX), cefixime (CFM), cotrimoxazole (SXT) and nitrofurantoin (FT), against 402 strains recently isolated from urine specimens in outpatient women suffering from lower urinary tract infections for which short-term treatment was not indicated." | 3.73 | [Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community]. ( Dib, C; Durand, C; Moniot-Ville, N; Weber, P, 2005) |
| "Two patients with acute leukemia developed Escherichia coli bacteremia while receiving oral ofloxacin for antibacterial prophylaxis during profound neutropenia." | 3.69 | Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. ( Andriof, E; Kern, WV; Markus, A, 1994) |
| "The in vivo efficacy of ofloxacin was compared with those of cefotaxime and doxycycline in a rat model of epididymitis due to Escherichia coli." | 3.68 | Comparative efficacies of ofloxacin, cefotaxime, and doxycycline for treatment of experimental epididymitis due to Escherichia coli in rats. ( Jantos, C; Schiefer, HG; Schmidts, HL; Vieler, E; Weidner, W, 1993) |
| "Ofloxacine (Tarivid-Hoechst) was used in 30 patients with infections of the respiratory system, including 12 with pneumonias, 18 with chronic bronchitis." | 3.68 | [Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract]. ( Chyrek-Borowska, S; Jakubicz, P; Siergiejko, Z, 1991) |
| "The effect of a single day treatment with 600 mg norfloxacin 600 mg ofloxacin or 1,920 mg trimethoprim-sulfamethoxazol was determined on 114 patients with acute cystitis." | 3.67 | [Single day treatment in acute cystitis]. ( Kawaguchi, K; Yamaguchi, K, 1988) |
| "The antibacterial activity of ofloxacin, a new gyrase inhibitor, was tested in experimental acute occlusive pyelonephritis in rats caused by Escherichia coli O4:H5 and Pseudomonas aeruginosa A 9532." | 3.67 | [Results of ofloxacin treatment of experimental urinary tract infections]. ( Ritzerfeld, W, 1986) |
| "A mouse model of subcutaneous abscess was used to determine the penetration into the abscess and the preventive value of ofloxacin (Hoe 280)." | 3.67 | Efficacy of ofloxacin (HOE 280) in a model of subcutaneous abscess: penetration and prevention of abscess formation. ( García Iglesias, MC; Perea, EJ, 1986) |
| "Levofloxacin's efficacy was inferior to azithromycin's efficacy, except in patients with no pathogen identified during the first 24 h of treatment or in patients with levofloxacin-susceptible Campylobacter isolates, in whom it appeared to be equal to azithromycin." | 2.73 | Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. ( Armstrong, A; Baqar, S; Bodhidatta, L; Faix, DJ; Fox, A; Hshieh, P; Lawler, JV; Lebron, C; Lewis, M; Maley, EA; Mason, C; Nayak, G; Pang, LW; Pitarangsi, C; Sanders, JW; Scott, DA; Tribble, DR, 2007) |
| "Ofloxacin was well tolerated: adverse events were reported by 67 (12." | 2.67 | Ofloxacin versus trimethoprim and co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. ( Cole, TP; Spencer, RC, 1992) |
| "Ofloxacin therapy was administered an average of 45 days per patient, and was well tolerated." | 2.67 | Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents. ( Eron, LJ; Gentry, LO, 1992) |
| " Among 33 patients given ofloxacin, the concentration of the drug in vaginal fluid during one dosage interval ranged from 1." | 2.66 | Pharmacodynamic evaluation of ofloxacin and trimethoprim-sulfamethoxazole in vaginal fluid of women treated for acute cystitis. ( Brust, P; Hooton, TM; Johnson, CR; Opheim, K; Stamm, WE; Tartaglione, TA, 1988) |
| "Fluoroquinolones are the most commonly used prophylactic antimicrobials for ultrasound-guided transrectal prostate biopsy due to their broad pathogen spectrum, pharmacokinetics, bioavailability and ease of oral administration." | 2.44 | Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature. ( Fujisawa, M; Miura, T; Nakano, Y; Shigemura, K; Takenaka, A; Tanaka, K, 2008) |
| "Renal parenchymal malacoplakia is a rare cause of acute renal failure." | 2.42 | Renal parenchymal malacoplakia: a rare cause of ARF with a review of recent literature. ( Chan, KW; Kung, WH; Li, R; Tam, VK, 2003) |
| "Ampicillin (84." | 1.48 | Multidrug resistance, prevalence and phylogenetic analysis of genes encoding class II and III integrons in clinically isolated Escherichia coli. ( Abdelwahab, SI; Dafalla, OME; Homeida, HE; Taha, MME, 2018) |
| "The empiric treatment of acute pyelonephritis (APN) with third generation cephalosporins (3GC) or fluoroquinolones (FQ) has been challenged by Escherichia coli resistance reported by community surveillance networks." | 1.40 | Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors. ( Caron, F; Choplin-Renard, J; Etienne, M; Pestel-Caron, M; Van Elslande, H, 2014) |
| " Using a similar dosing selection pressure, the emergence of levofloxacin resistance was delayed in a strain with acrAB deleted compared to the isogenic parent." | 1.38 | Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. ( Hu, M; Ledesma, KR; Singh, R; Swick, MC; Tam, VH; Yang, Z; Zechiedrich, L, 2012) |
| "coli." | 1.37 | Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy. ( Baba, S; Fujita, T; Iwamura, M; Kimura, M; Kurosaka, S; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K; Tsumura, H, 2011) |
| "Pyelonephritis is rarely considered in the differential diagnosis of acute kidney injury." | 1.37 | Acute kidney injury from pyelonephritis in an elderly man: case report. ( Alroumoh, M; El-Kass, G; Galler, M; Husain, S; Mohan, P; Seshan, SV, 2011) |
| "Levofloxacin seems to be a good alternative treatment for patients with uncomplicated spontaneous ascites infections." | 1.36 | A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. ( Alişkan, H; Güçlü, M; Husamettin, E; Serin, E; Yakar, T, 2010) |
| "He suddenly fell into septic shock about 12 hours after the biopsy." | 1.36 | [Septic shock due to fluoroquinolone-resistant Escherichia coli after trans-rectal prostate needle biopsy]. ( Fujishima, Y; Kato, R; Matsuura, T; Obara, W; Sato, K; Shimaya, R; Suzuki, Y; Tokiwa, S, 2010) |
| "Bilateral Acanthamoeba keratitis was diagnosed by culture using nonnutrient agar overlaid with viable Escherichia coli." | 1.36 | Bilateral acanthamoeba keratitis after orthokeratology. ( Kim, EC; Kim, MS, 2010) |
| "G6PD deficiency is very frequent with almost 400 millions of patients worldwide in Asia, Africa and Mediterranean." | 1.35 | [Ofloxacin is contraindicated in case of G6PD deficiency: is it evidenced based?]. ( Algayres, JP; Bonnefoy, S; Bordier, L; Callot, D; Carmoi, T; Lecoules, S, 2009) |
| "A correlation was seen between both the area under the serum concentration curve and MIC (AUC/MIC) and the peak concentration/MIC (Cmax/MIC) versus area under the bactericidal killing curve (AUBKC) or Deltalog0-24 cfu/mL." | 1.33 | Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. ( Cars, O; Odenholt, I, 2006) |
| "Moxifloxacin has been suggested as an option for monotherapy of intra-abdominal infections." | 1.33 | Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. ( Hermsen, ED; Hovde, LB; Rodvold, KA; Rotschafer, JC; Sprandel, KA, 2005) |
| "Ofloxacin was active against all but one (Pseudomonas aeruginosa) blood culture isolates." | 1.27 | Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients. ( Alkan, M; Berger, S; Bogokowski, B; Keren, G; Mark, Z; Rubinstein, E, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (12.50) | 18.7374 |
| 1990's | 16 (18.18) | 18.2507 |
| 2000's | 30 (34.09) | 29.6817 |
| 2010's | 29 (32.95) | 24.3611 |
| 2020's | 2 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Segawa, J | 1 |
| Kitano, M | 1 |
| Kazuno, K | 1 |
| Matsuoka, M | 1 |
| Shirahase, I | 1 |
| Ozaki, M | 1 |
| Matsuda, M | 1 |
| Tomii, Y | 1 |
| Kise, M | 1 |
| Mendonça, N | 1 |
| Leitão, J | 1 |
| Manageiro, V | 1 |
| Ferreira, E | 1 |
| Caniça, M | 1 |
| Cattoir, V | 2 |
| Poirel, L | 1 |
| Nordmann, P | 1 |
| Blango, MG | 1 |
| Mulvey, MA | 1 |
| Prasada Rao, CMM | 1 |
| Vennila, T | 1 |
| Kosanam, S | 1 |
| Ponsudha, P | 1 |
| Suriyakrishnaan, K | 1 |
| Alarfaj, AA | 1 |
| Hirad, AH | 1 |
| Sundaram, SR | 1 |
| Surendhar, PA | 1 |
| Selvam, N | 1 |
| Ma, WJ | 1 |
| Wu, ZR | 1 |
| Yang, Q | 1 |
| Hu, HJ | 1 |
| Wang, JK | 1 |
| Shi, YJ | 1 |
| Li, FY | 1 |
| Cheng, NS | 1 |
| Lei, L | 1 |
| Rehman, MU | 1 |
| Huang, S | 1 |
| Zhang, L | 1 |
| Wang, L | 1 |
| Mehmood, K | 1 |
| Zhang, H | 1 |
| Tong, X | 1 |
| Wang, M | 1 |
| Li, J | 1 |
| Taha, MME | 1 |
| Homeida, HE | 1 |
| Dafalla, OME | 1 |
| Abdelwahab, SI | 1 |
| Ouni, B | 1 |
| Fathallah, N | 1 |
| Slim, R | 1 |
| Brahim, A | 1 |
| Ben Salem, C | 1 |
| Etienne, M | 1 |
| Van Elslande, H | 1 |
| Choplin-Renard, J | 1 |
| Pestel-Caron, M | 1 |
| Caron, F | 1 |
| Bedoin, M | 1 |
| Cazorla, C | 1 |
| Lucht, F | 1 |
| Berthelot, P | 1 |
| Boyer, M | 1 |
| Carricajo, A | 1 |
| Guérin, T | 1 |
| Viallon, A | 1 |
| Abdul Qadir, M | 1 |
| Shahzad, S | 1 |
| Rasheed, R | 1 |
| Ahmed, M | 1 |
| Anwar, S | 1 |
| Kiran Shahzadi, S | 1 |
| Rasool, MH | 1 |
| Siddique, AB | 1 |
| Saqalein, M | 1 |
| Asghar, MJ | 1 |
| Zahoor, MA | 1 |
| Aslam, B | 1 |
| Shafiq, HB | 1 |
| Nisar, MA | 1 |
| Ullah, O | 1 |
| Khan, A | 1 |
| Ambreen, A | 1 |
| Ahmad, I | 1 |
| Akhtar, T | 1 |
| Gandapor, AJ | 1 |
| Khan, AM | 1 |
| Sanders, JW | 2 |
| Frenck, RW | 1 |
| Putnam, SD | 1 |
| Riddle, MS | 1 |
| Johnston, JR | 1 |
| Ulukan, S | 1 |
| Rockabrand, DM | 1 |
| Monteville, MR | 1 |
| Tribble, DR | 2 |
| Carmoi, T | 1 |
| Bordier, L | 1 |
| Bonnefoy, S | 1 |
| Callot, D | 1 |
| Lecoules, S | 1 |
| Algayres, JP | 1 |
| Talan, DA | 1 |
| Krishnadasan, A | 1 |
| Abrahamian, FM | 1 |
| Stamm, WE | 2 |
| Moran, GJ | 1 |
| Johnson, L | 1 |
| Sabel, A | 1 |
| Burman, WJ | 1 |
| Everhart, RM | 1 |
| Rome, M | 1 |
| MacKenzie, TD | 1 |
| Rozwadowski, J | 1 |
| Mehler, PS | 1 |
| Price, CS | 1 |
| Yakar, T | 1 |
| Güçlü, M | 1 |
| Serin, E | 1 |
| Alişkan, H | 1 |
| Husamettin, E | 1 |
| Kim, EC | 1 |
| Kim, MS | 1 |
| Drago, L | 2 |
| Nicola, L | 1 |
| Mattina, R | 1 |
| De Vecchi, E | 1 |
| Kato, R | 1 |
| Suzuki, Y | 1 |
| Matsuura, T | 1 |
| Sato, K | 3 |
| Shimaya, R | 1 |
| Fujishima, Y | 1 |
| Tokiwa, S | 1 |
| Obara, W | 1 |
| Yasufuku, T | 1 |
| Shigemura, K | 2 |
| Shirakawa, T | 1 |
| Nakano, Y | 2 |
| Tanaka, K | 2 |
| Arakawa, S | 1 |
| Kinoshita, S | 1 |
| Nishimura, K | 1 |
| Kawabata, M | 1 |
| Fujisawa, M | 2 |
| Cuevas, O | 1 |
| Oteo, J | 1 |
| Lázaro, E | 1 |
| Aracil, B | 1 |
| de Abajo, F | 1 |
| García-Cobos, S | 1 |
| Ortega, A | 1 |
| Campos, J | 1 |
| Deguchi, T | 2 |
| Seike, K | 1 |
| Yasuda, M | 2 |
| Matsumoto, T | 1 |
| Wagenlehner, F | 1 |
| Roscher, K | 1 |
| Naber, KG | 1 |
| Cai, T | 1 |
| Mazzoli, S | 1 |
| Meacci, F | 1 |
| Boddi, V | 1 |
| Mondaini, N | 1 |
| Malossini, G | 1 |
| Bartoletti, R | 1 |
| Husain, S | 1 |
| Alroumoh, M | 1 |
| Mohan, P | 1 |
| El-Kass, G | 1 |
| Seshan, SV | 1 |
| Galler, M | 1 |
| Minamida, S | 1 |
| Satoh, T | 1 |
| Tabata, K | 1 |
| Kimura, M | 1 |
| Tsumura, H | 1 |
| Kurosaka, S | 1 |
| Matsumoto, K | 1 |
| Fujita, T | 1 |
| Iwamura, M | 1 |
| Baba, S | 1 |
| Yamane, T | 1 |
| Enokida, H | 1 |
| Hayami, H | 1 |
| Kawahara, M | 1 |
| Nakagawa, M | 1 |
| Singh, R | 1 |
| Swick, MC | 1 |
| Ledesma, KR | 1 |
| Yang, Z | 1 |
| Hu, M | 1 |
| Zechiedrich, L | 1 |
| Tam, VH | 1 |
| Yokota, S | 1 |
| Sato, T | 1 |
| Okubo, T | 1 |
| Ohkoshi, Y | 1 |
| Okabayashi, T | 1 |
| Kuwahara, O | 1 |
| Tamura, Y | 1 |
| Fujii, N | 3 |
| Sousa, I | 1 |
| Claro, V | 1 |
| Pereira, JL | 1 |
| Amaral, AL | 1 |
| Cunha-Silva, L | 1 |
| de Castro, B | 1 |
| Feio, MJ | 1 |
| Pereira, E | 1 |
| Gameiro, P | 1 |
| Elgorriaga-Islas, E | 1 |
| Guggiana-Nilo, P | 1 |
| Domínguez-Yévenes, M | 1 |
| González-Rocha, G | 1 |
| Mella-Montecinos, S | 1 |
| Labarca-Labarca, J | 1 |
| García-Cañete, P | 1 |
| Bello-Toledo, H | 1 |
| Jamal, T | 1 |
| Rahman, MA | 1 |
| Mirza, MA | 1 |
| Panda, AK | 1 |
| Talegaonkar, S | 1 |
| Iqbal, Z | 1 |
| Zhang, ZC | 1 |
| Jin, FS | 1 |
| Liu, DM | 1 |
| Shen, ZJ | 2 |
| Sun, YH | 1 |
| Guo, YL | 1 |
| Ohnishi, K | 1 |
| Nakamura-Uchiyama, F | 1 |
| Qin, GD | 1 |
| Xiao, MZ | 1 |
| Zhou, YD | 1 |
| Yang, J | 1 |
| He, HX | 1 |
| He, Y | 1 |
| Zeng, Y | 1 |
| Hiramatsu, K | 1 |
| Murakami, J | 1 |
| Kishi, K | 1 |
| Hirata, N | 1 |
| Yamasaki, T | 1 |
| Kadota, J | 1 |
| Shibata, T | 1 |
| Nasu, M | 1 |
| Tam, VK | 1 |
| Kung, WH | 1 |
| Li, R | 1 |
| Chan, KW | 1 |
| Seo, SI | 1 |
| Lee, SJ | 1 |
| Kim, JC | 1 |
| Choi, YJ | 1 |
| SW, SW | 1 |
| Hwang, TK | 1 |
| Cho, YH | 1 |
| Meiland, R | 1 |
| Geerlings, SE | 1 |
| De Neeling, AJ | 1 |
| Hoepelman, AI | 1 |
| Liapakis, IE | 1 |
| Kottakis, I | 1 |
| Tzatzarakis, MN | 1 |
| Tsatsakis, AM | 1 |
| Pitiakoudis, MS | 1 |
| Ypsilantis, P | 1 |
| Light, RW | 1 |
| Simopoulos, CE | 1 |
| Bouros, DE | 1 |
| Hermsen, ED | 1 |
| Hovde, LB | 1 |
| Sprandel, KA | 1 |
| Rodvold, KA | 1 |
| Rotschafer, JC | 1 |
| Weber, P | 2 |
| Dib, C | 1 |
| Durand, C | 1 |
| Moniot-Ville, N | 1 |
| Mahamat, A | 1 |
| Lavigne, JP | 1 |
| Fabbro-Peray, P | 1 |
| Kinowski, JM | 1 |
| Daurès, JP | 1 |
| Sotto, A | 1 |
| Chen, SW | 1 |
| Wang, H | 1 |
| Zhou, XL | 1 |
| Zhao, JP | 1 |
| Pust, RA | 1 |
| Ackenheil-Koppe, HR | 1 |
| Gilbert, P | 1 |
| Weidner, W | 2 |
| Lautenbach, E | 1 |
| Fishman, NO | 1 |
| Metlay, JP | 1 |
| Mao, X | 1 |
| Bilker, WB | 1 |
| Tolomeo, P | 1 |
| Nachamkin, I | 1 |
| Odenholt, I | 1 |
| Cars, O | 1 |
| Lesprit, P | 1 |
| Lascols, C | 2 |
| Denamur, E | 1 |
| Legrand, P | 1 |
| Soussy, CJ | 2 |
| Cambau, E | 1 |
| Esposito, S | 1 |
| Noviello, S | 1 |
| Leone, S | 1 |
| Marvaso, A | 1 |
| Marchetti, F | 1 |
| Pang, LW | 1 |
| Mason, C | 1 |
| Pitarangsi, C | 1 |
| Baqar, S | 1 |
| Armstrong, A | 1 |
| Hshieh, P | 1 |
| Fox, A | 1 |
| Maley, EA | 1 |
| Lebron, C | 1 |
| Faix, DJ | 1 |
| Lawler, JV | 1 |
| Nayak, G | 1 |
| Lewis, M | 1 |
| Bodhidatta, L | 1 |
| Scott, DA | 1 |
| Gualco, L | 1 |
| Schito, AM | 1 |
| Schito, GC | 1 |
| Marchese, A | 1 |
| Dib-Smahi, C | 1 |
| Nicolle, L | 1 |
| Duckworth, H | 1 |
| Sitar, D | 1 |
| Bryski, L | 1 |
| Harding, G | 1 |
| Zhanel, G | 1 |
| Miura, T | 1 |
| Takenaka, A | 1 |
| Saito, M | 1 |
| Seo, T | 1 |
| Matsubara, Y | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Ito, K | 1 |
| Konishi, K | 1 |
| Matsunaga, M | 1 |
| Yanagishita, T | 1 |
| Kosugi, M | 1 |
| Plaisance, JJ | 1 |
| Mancy, C | 1 |
| Kern, WV | 2 |
| Markus, A | 1 |
| Andriof, E | 2 |
| Oethinger, M | 1 |
| Kern, P | 1 |
| Hacker, J | 1 |
| Marre, R | 1 |
| Brook, I | 1 |
| Ledney, GD | 1 |
| Tatlişen, A | 1 |
| Carpinlioğlu, M | 1 |
| Sümerkan, B | 1 |
| Gülmez, I | 1 |
| Karacagil, M | 1 |
| Pfau, A | 1 |
| Vieler, E | 1 |
| Jantos, C | 1 |
| Schmidts, HL | 1 |
| Schiefer, HG | 1 |
| Kumagai, Y | 1 |
| Kato, JI | 1 |
| Hoshino, K | 1 |
| Akasaka, T | 1 |
| Ikeda, H | 1 |
| Karachalios, GN | 1 |
| Nasiopoulou, DD | 1 |
| Bourlinou, PK | 1 |
| Reppa, A | 1 |
| Ozeki, S | 1 |
| Nakano, M | 1 |
| Kawamura, T | 1 |
| Nishino, Y | 1 |
| Kawada, Y | 1 |
| Ortiz, J | 1 |
| Vila, MC | 1 |
| Soriano, G | 1 |
| Miñana, J | 1 |
| Gana, J | 1 |
| Mirelis, B | 1 |
| Novella, MT | 1 |
| Coll, S | 1 |
| Sábat, M | 1 |
| Andreu, M | 1 |
| Prats, G | 1 |
| Solá, R | 1 |
| Guarner, C | 1 |
| Baril, L | 1 |
| Maisonobe, T | 1 |
| Jasson-Molinier, M | 1 |
| Haroche, J | 1 |
| Bricaire, F | 1 |
| Caumes, E | 1 |
| Miedouge, M | 1 |
| Hacini, J | 1 |
| Grimont, F | 1 |
| Watine, J | 1 |
| Koyama, Y | 1 |
| Mikami, O | 1 |
| Matsuda, T | 1 |
| Murota, T | 1 |
| Ohara, T | 1 |
| Kawamura, H | 1 |
| Amazutsumi, K | 1 |
| Uchida, J | 1 |
| Harada, T | 1 |
| Isogai, E | 3 |
| Isogai, H | 3 |
| Hayashi, S | 3 |
| Kubota, T | 2 |
| Kimura, K | 2 |
| Ohtani, T | 1 |
| Hirose, K | 2 |
| Oguma, K | 2 |
| Takeshi, K | 1 |
| Baskin, H | 1 |
| Doğan, Y | 1 |
| Bahar, IH | 1 |
| Yuluğ, N | 1 |
| Spencer, RC | 1 |
| Cole, TP | 1 |
| Eron, LJ | 1 |
| Gentry, LO | 1 |
| Chyrek-Borowska, S | 1 |
| Siergiejko, Z | 1 |
| Jakubicz, P | 1 |
| Unal, S | 1 |
| Aydin, M | 1 |
| Dervişoğlu, AA | 1 |
| Obana, Y | 1 |
| Nishino, T | 1 |
| Yamaguchi, K | 1 |
| Kawaguchi, K | 1 |
| Seiga, K | 1 |
| Syoji, T | 1 |
| Tsuchiyama, K | 1 |
| Sugiyama, Y | 1 |
| Tartaglione, TA | 1 |
| Johnson, CR | 1 |
| Brust, P | 1 |
| Opheim, K | 1 |
| Hooton, TM | 1 |
| Ode, B | 1 |
| Walder, M | 1 |
| Forsgren, A | 1 |
| Rubinstein, E | 1 |
| Mark, Z | 1 |
| Keren, G | 1 |
| Alkan, M | 1 |
| Berger, S | 1 |
| Bogokowski, B | 1 |
| Ritzerfeld, W | 1 |
| García Iglesias, MC | 1 |
| Perea, EJ | 1 |
2 reviews available for ofloxacin and Escherichia coli Infections
| Article | Year |
|---|---|
Renal parenchymal malacoplakia: a rare cause of ARF with a review of recent literature.
Topics: Acute Kidney Injury; Aged; Biopsy, Needle; Cefuroxime; Diagnosis, Differential; Drug Therapy, Combin | 2003 |
Levofloxacin resistant Escherichia coli sepsis following an ultrasound-guided transrectal prostate biopsy: report of four cases and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli | 2008 |
11 trials available for ofloxacin and Escherichia coli Infections
| Article | Year |
|---|---|
Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey.
Topics: Adult; Azithromycin; Campylobacter Infections; Diarrhea; Double-Blind Method; Drug Therapy, Combinat | 2007 |
Safety and efficacy of levofloxacin versus ciprofloxacin for the treatment of chronic bacterial prostatitis in Chinese patients.
Topics: Adult; Anti-Bacterial Agents; Asian People; Ciprofloxacin; Escherichia coli Infections; Humans; Levo | 2012 |
A pilot study on prevention of catheter-related urinary tract infections with fluoroquinolones.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; | 2006 |
Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Campylobacter Infections; Campylobacter jejuni; Communit | 2007 |
[Comparison of clinical efficacy of ofloxacin COFLX: DL-8280) and pipemidic acid (PPA) in acute infectious diarrhea by a double-blind method. The Japan Research Committee of Ofloxacin, Research Group for Acute Infectious Diarrhea].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Campylobacter I | 1984 |
Treatment of acute biliary tract infections with ofloxacin: a randomized, controlled clinical trial.
Topics: Anti-Infective Agents; Bacteremia; Ceftriaxone; Cephalosporins; Cholangitis; Cholecystitis; Escheric | 1996 |
[Efficacy of single-dose therapy with levofloxacin for acute cystitis: comparison to three-day therapy].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Child | 2000 |
Ofloxacin versus trimethoprim and co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice.
Topics: Adult; Aged; Escherichia coli Infections; Family Practice; Female; Humans; Male; Middle Aged; Ofloxa | 1992 |
Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Diabetes Complications; Drug Resistance, Mi | 1992 |
Pharmacodynamic evaluation of ofloxacin and trimethoprim-sulfamethoxazole in vaginal fluid of women treated for acute cystitis.
Topics: Administration, Oral; Adult; Body Fluids; Cystitis; Drug Administration Schedule; Drug Combinations; | 1988 |
Failure of a single dose of 100 mg ofloxacin in lower urinary tract infections in females.
Topics: Anti-Infective Agents, Urinary; Clinical Trials as Topic; Drug Combinations; Escherichia coli Infect | 1987 |
75 other studies available for ofloxacin and Escherichia coli Infections
| Article | Year |
|---|---|
Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3- carboxylic acids.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Carboxylic Acids; Escherichia coli Infections; | 1992 |
Spread of extended-spectrum beta-lactamase CTX-M-producing escherichia coli clinical isolates in community and nosocomial environments in Portugal.
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Community-Acquired Infections; Cross Infection; Drug R | 2007 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Esch | 2008 |
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistan | 2010 |
Assessment of Bacterial Isolates from the Urine Specimens of Urinary Tract Infected Patient.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli | 2022 |
Biliary antibiotics irrigation for E. coli-induced chronic proliferative cholangitis and hepatolithiasis: A pathophysiological study in rabbits.
Topics: Animals; Anti-Bacterial Agents; Bacitracin; Chlorhexidine; Cholangitis; Chronic Disease; Collagen Ty | 2020 |
Antimicrobial resistance and prevalence of diarrheagenic Escherichia coli (DEC), in diarrheic yaks of Tibetan Plateau, China.
Topics: Animals; Anti-Bacterial Agents; Cattle; Cattle Diseases; China; Diarrhea; Drug Resistance, Bacterial | 2018 |
Multidrug resistance, prevalence and phylogenetic analysis of genes encoding class II and III integrons in clinically isolated Escherichia coli.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; Base Sequence; Cefotaxime; Ciprofloxacin; Drug Resistan | 2018 |
Anaphylactic shock secondary to oral ofloxacin administration with cross-reactivity to levofloxacin and ciprofloxacin.
Topics: Administration, Oral; Adolescent; Anaphylaxis; Ciprofloxacin; Cross Reactions; Drug Hypersensitivity | 2018 |
Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Catchment Area, Heal | 2014 |
Risk factors for quinolone-resistance in women presenting with Escherichia coli acute pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Catchment Area, Health; Cohort St | 2014 |
A Novel Method for the Synthesis of (99m)Tc-Ofloxacin Kits Using D-Penicillamine as Coligand and Their Application as Infection Imaging Agent.
Topics: Animals; Escherichia coli; Escherichia coli Infections; Humans; Isotope Labeling; Ofloxacin; Pseudom | 2015 |
Occurrence and antibacterial susceptibility pattern of bacterial pathogens isolated from diarrheal patients in Pakistan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bacillus cereus; Cef | 2016 |
Antibiotic Sensitivity pattern of Bacterial Isolates of Neonatal Septicemia in Peshawar, Pakistan.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacteri | 2016 |
[Ofloxacin is contraindicated in case of G6PD deficiency: is it evidenced based?].
Topics: Contraindications; Diabetes Complications; Escherichia coli Infections; Female; Glucosephosphate Deh | 2009 |
Prevalence and risk factor analysis of trimethoprim-sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ciprofloxacin; Cross-Sectional Studies; Drug Resistance, | 2008 |
Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Drug Resist | 2008 |
A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ascitic Fluid; Bacterial Infections; Cefepime | 2010 |
Bilateral acanthamoeba keratitis after orthokeratology.
Topics: Acanthamoeba Keratitis; Antiprotozoal Agents; Biguanides; Drug Therapy, Combination; Escherichia col | 2010 |
In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Dioxolanes; DNA Gyrase; DNA Mutational Ana | 2010 |
[Septic shock due to fluoroquinolone-resistant Escherichia coli after trans-rectal prostate needle biopsy].
Topics: Biopsy, Needle; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Humans; L | 2010 |
Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, B | 2011 |
Significant ecological impact on the progression of fluoroquinolone resistance in Escherichia coli with increased community use of moxifloxacin, levofloxacin and amoxicillin/clavulanic acid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Aza Compo | 2011 |
Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Area Under Curve; Computer Simulation; Databases, Factual; Escherichia coli; | 2011 |
[Practice management of chronic bacterial prostatitis with levofloxacin].
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Bacterial Infections; Chronic Disease; Escherichia coli | 2011 |
Epidemiological features and resistance pattern in uropathogens isolated from chronic bacterial prostatitis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Enterococcus fa | 2011 |
Acute kidney injury from pyelonephritis in an elderly man: case report.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Diagnosis, Differential; | 2011 |
Prevalence of fluoroquinolone-resistant Escherichia coli before and incidence of acute bacterial prostatitis after prostate biopsy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Needle; Carba | 2011 |
Genome-wide transcriptome analysis of fluoroquinolone resistance in clinical isolates of Escherichia coli.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Ciproflo | 2012 |
Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.
Topics: Anti-Bacterial Agents; Area Under Curve; Culture Media; DNA Gyrase; DNA Topoisomerase IV; Drug Resis | 2012 |
Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamases; Child; Child, Pr | 2012 |
Synthesis, characterization and antibacterial studies of a copper(II) levofloxacin ternary complex.
Topics: Anti-Bacterial Agents; Copper; Escherichia coli; Escherichia coli Infections; Levofloxacin; Ofloxaci | 2012 |
[Prevalence of plasmid-mediated quinolone resistance determinant aac(6')-Ib-cr among ESBL producing enterobacteria isolates from Chilean hospitals].
Topics: Acetylation; Anti-Bacterial Agents; Bacterial Proteins; Chile; Ciprofloxacin; Cross Infection; Drug | 2012 |
Formulation, antimicrobial and toxicity evaluation of bioceramic based ofloxacin loaded biodegradable microspheres for periodontal infection.
Topics: Animals; Anti-Bacterial Agents; Cell Survival; Chemistry, Pharmaceutical; Escherichia coli; Escheric | 2012 |
Does levofloxacin induce hemolytic uremic syndrome in patients infected with verotoxin-producing Escherichia coli O157 infections?
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Colitis; Escherichia coli Infections; Escherichi | 2012 |
Tamsulosin alters levofloxacin pharmacokinetics in prostates derived from rats with acute bacterial prostatitis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Anti-Bacterial Agents; Drug Interactions; Escheric | 2013 |
Treatment with rokitamycin suppresses the lethality in a murine model of Escherichia coli O157:H7 infection.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Colony Count, Microbial; Disease Models, Anim | 2003 |
Effects of androgen deprivation on chronic bacterial prostatitis in a rat model.
Topics: Androgen Antagonists; Animals; Anti-Infective Agents, Urinary; Castration; Chronic Disease; Enzyme I | 2003 |
Diabetes mellitus in itself is not a risk factor for antibiotic resistance in Escherichia coli isolated from patients with bacteriuria.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Bacteriuria; Ciprofloxacin; Diabetes Co | 2004 |
Penetration of newer quinolones in the empyema fluid.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Empyema, Pleural; Escherichia coli Infections; Fluoro | 2004 |
Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteroides fragilis; Bacteroides Infections; Chromatography, | 2005 |
[Evaluation of levofloxacin susceptibility against strains isolated from lower urinary tract infections in the community].
Topics: Anti-Infective Agents, Urinary; Bacterial Infections; Community-Acquired Infections; Escherichia col | 2005 |
Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli | 2005 |
Life-threatening meningitis resulting from transrectal prostate biopsy.
Topics: Adenocarcinoma; Aged; Anti-Infective Agents; Anti-Infective Agents, Urinary; Biopsy; Escherichia col | 2005 |
Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Escherichia coli Infec | 1989 |
Phenotypic and genotypic characterization of fecal Escherichia coli isolates with decreased susceptibility to fluoroquinolones: results from a large hospital-based surveillance initiative.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Electrophoresis, Gel, Pulsed-Field; Escheri | 2006 |
Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Escherichia coli; Escherichia coli | 2006 |
In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; DNA Topoisomerases; Drug Resistance; Escherichia coli; Esch | 2006 |
In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.
Topics: Anti-Infective Agents, Urinary; Bacterial Adhesion; Ciprofloxacin; Dioxolanes; Drug Resistance, Bact | 2007 |
[In vitro activity of levofloxacin against Escherichia coli strains in acute pyelonephritis, in France in 2005].
Topics: Acute Disease; Anti-Bacterial Agents; Escherichia coli; Escherichia coli Infections; France; Humans; | 2007 |
Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Escherichia coli Infections; F | 2008 |
Lack of increase in resistance to quinolones in general practice isolates of Escherichia coli.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Clavulanic Acids; | 1994 |
Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Infective Agents; Bacteremia; Drug Resistance, Micr | 1994 |
Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.
Topics: Anti-Infective Agents; Cancer Care Facilities; Cross Infection; Drug Resistance, Microbial; Drug Uti | 1994 |
The treatment of irradiated mice with polymicrobial infection caused by Bacteroides fragilis and Escherichia coli.
Topics: Abscess; Animals; Bacteria, Anaerobic; Bacteroides fragilis; Bacteroides Infections; Drug Resistance | 1994 |
[Evaluation of 18 epididymo-orchitis cases].
Topics: Adolescent; Adult; Bacteriuria; Brucellosis; Doxycycline; Drug Therapy, Combination; Epididymitis; E | 1993 |
Oral ofloxacin: a critical review of the new drug application.
Topics: Administration, Oral; Escherichia coli Infections; Humans; Investigational New Drug Application; Mal | 1993 |
Comparative efficacies of ofloxacin, cefotaxime, and doxycycline for treatment of experimental epididymitis due to Escherichia coli in rats.
Topics: Animals; Cefotaxime; Doxycycline; Epididymitis; Escherichia coli; Escherichia coli Infections; Male; | 1993 |
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.
Topics: Anti-Infective Agents; Base Sequence; Cloning, Molecular; Culture Media; DNA Topoisomerase IV; DNA T | 1996 |
Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Asparagine; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; DNA, Bact | 1997 |
Infections caused by Escherichia coli resistant to norfloxacin in hospitalized cirrhotic patients.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Ciprofloxacin; Drug Resi | 1999 |
Acute rhabdomyolysis during treatment with ofloxacin-a case report.
Topics: Acute Disease; Anti-Infective Agents; Escherichia coli Infections; Female; Humans; Middle Aged; Oflo | 1999 |
Shiga toxin-producing Escherichia coli urinary tract infection associated with hemolytic-uremic syndrome in an adult and possible adverse effect of ofloxacin therapy.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Escherichia coli Infections; Escherichia coli O157; Fem | 2000 |
Effect of antibiotics, levofloxacin and fosfomycin, on a mouse model with Escherichia coli O157 infection.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Toxins; Diarrhea; Disease Models, A | 2000 |
In vivo synergy between green tea extract and levofloxacin against enterohemorrhagic Escherichia coli O157 infection.
Topics: Animals; Anti-Infective Agents; Catechin; Colony Count, Microbial; Drug Synergism; Enzyme-Linked Imm | 2001 |
Therapeutic effect of anti-TNF-alpha antibody and levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection.
Topics: Animals; Anti-Infective Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Disease Models, Anima | 2001 |
Effect of subminimal inhibitory concentrations of three fluoroquinolones on adherence of uropathogenic strains of Escherichia coli.
Topics: Anti-Infective Agents; Bacterial Adhesion; Cell Line; Ciprofloxacin; Escherichia coli; Escherichia c | 2002 |
[Evaluation of the effectiveness of ofloxacin in the treatment of respiratory tract].
Topics: Administration, Oral; Adult; Aged; Bronchitis; Chronic Disease; Drug Resistance, Microbial; Enteroco | 1991 |
[An epidemiologic study of the antibiotic susceptibility of bacteria isolated from patients with urinary tract infections].
Topics: Adolescent; Adult; Amikacin; Anti-Bacterial Agents; Bacteria; Cefotaxime; Escherichia coli; Escheric | 1989 |
In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Mice; Microbial | 1989 |
[Single day treatment in acute cystitis].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Cystitis; | 1988 |
[Second report of ofloxacin: clinical study].
Topics: Adult; Escherichia coli Infections; Female; Fetal Blood; Genital Diseases, Female; Humans; Maternal- | 1988 |
Comparative activity of ofloxacin with reference to bacterial strains isolated in in-patients and out-patients.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cross Infection; Dose-Response Relationship, | 1986 |
[Results of ofloxacin treatment of experimental urinary tract infections].
Topics: Animals; Anti-Infective Agents, Urinary; Dose-Response Relationship, Drug; Escherichia coli Infectio | 1986 |
Efficacy of ofloxacin (HOE 280) in a model of subcutaneous abscess: penetration and prevention of abscess formation.
Topics: Abscess; Animals; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; Escherichia c | 1986 |